Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma-Reference-Cited by-同舟云学术

Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma

Published:2020-10 Issue:5 Volume:34 Page:861-870
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Guy Daniel,Kahl Brad S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference36 articles.

1. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma;Khouri;J Clin Oncol,1998

2. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine;Romaguera;J Clin Oncol,2005

3. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center;Chihara;Br J Haematol,2016

4. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma;Romaguera;Br J Haematol,2010

5. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi;Merli;Br J Haematol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions;Journal of Clinical Medicine;2021-03-14

2. MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway;OncoTargets and Therapy;2021-03